771 A phase 1 study to assess safety, efficacy, pharmacokinetics, and pharmacodynamics of intratumoral CLN-617 (IL2/IL12 fusion protein) combined with pembrolizumab in patients wit... by Evan Hall, Adi Diab, Sajeve Thomas, Randy Sweis, Anthony El-Khoueiry, Naveen K Mehta, Jennifer S Michaelson, Laura Liu, Reham Abdel-Wahab, Jeffrey A Jones, Kaida Wu, Benjamin S Maciejewski

756 First-in-human, open-label, multicenter, phase 1 clinical study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of anti Siglec-15 PYX-106 in subjects wi... by Bin Zhang, Marsha Crochiere, Anthony W Tolcher, Randy Sweis, Kartik Sehgal, Michael S Gordon, Shui He, Jason Henry, Alexander I Spira, Shiraj Sen, Sandip P Patel, Sondra Smyrnios, Dipali Unadkat

726 Establishing proof of mechanism in patients: preliminary biomarker data of SRK-181 (a latent TGFβ1 inhibitor) from DRAGON Study by Minal Barve, Ahmad A Tarhini, Deepak Kilari, Randy Sweis, Timothy Yap, John Clark, Justin Gainor, Lu Gan, Ulka N Vaishampayan, Amna Sher, Yawen Ju, Susan Henry, Stephen DeWall, Asia McCune, Mo Qatanani

666 Safety, efficacy, and biomarker results of SRK-181, a latent TGFβ1 inhibitor, in anti-PD-1 resistant metastatic ccRCC patients by Minal Barve, Ahmad A Tarhini, Deepak Kilari, Rana Mckay, Randy Sweis, Timothy Yap, Justin Gainor, Raghad Karim, Lu Gan, Lan Liu, David Park, Ulka N Vaishampayan, Amna Sher, Sunil Babu, Yawen Ju, Susan Henry